This multicenter prospective diagnostic accuracy study will compare the performance of three artificial intelligence (AI) models (MVCS, LungDoc, and a United Imaging AI model) for predicting the malignancy risk of pulmonary nodules on chest CT. All enrolled patients will have pulmonary nodules ≤3 cm on CT and a definitive postoperative or biopsy pathological diagnosis. The AI models will generate continuous malignancy probability scores based only on CT images. Pathology will serve as the gold standard.
The primary objective is to compare the area under the receiver operating characteristic curve (AUC) for malignancy prediction among the three AI models. Secondary objectives include comparison of sensitivity, specificity, positive and negative predictive values, accuracy, F1 score, and calibration. Exploratory analyses will evaluate the MVCS model for predicting pathological invasion degree (pre-invasive, minimally invasive, and invasive adenocarcinoma) and an extended MVCSN model that incorporates clinical and imaging features in a data-complete subset.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years, any sex.
* At least one pulmonary nodule detected on chest CT, with initial nodule diameter ≤ 3 cm.
* The nodule undergoes surgical resection or biopsy with a definitive benign or malignant pathological diagnosis.
* Time interval between CT examination and pathological examination ≤ 6 months.
* Availability of complete CT imaging data in DICOM format with adequate image quality (no severe artifacts), meeting input requirements of all three AI models.
Availability of complete clinicopathologic information including histologic type and grade, with clear pathological diagnosis suitable as gold standard labels for AI validation.
-The patient (or legally authorized representative) is willing and able to sign written informed consent.
Exclusion Criteria:
* Pathological results are unclear, inconclusive, or disputed; nodule nature or grade cannot be reliably determined.
* The patient receives treatments between CT and pathology that may significantly alter nodule appearance (e.g., chemotherapy, radiotherapy, targeted therapy).
* CT imaging data are incomplete (missing essential series) or have severe motion, metal, or other artifacts preventing accurate AI analysis.
* Required metadata for any AI model are missing and cannot be imputed. History of other malignant tumors (malignancies other than the index non-small cell lung cancer).
* Severe psychiatric illness, cognitive impairment, or other conditions that prevent cooperation with study-related procedures and follow-up.
Participation in another clinical study that may interfere with the results of this research.
-The patient or legal representative refuses participation.
Exclusion (Post-Enrollment / Removal from Analysis)
Participants already enrolled may be excluded from the analysis set if:
* They are later found not to meet inclusion criteria or to meet exclusion criteria.
* No usable data are available after enrollment.
* Required AI model assessments are not completed (e.g., technical failure to generate outputs).
* Critical data are missing, preventing contribution to primary analysis.
* The interval between CT and pathology exceeds 6 months.
Primary outcome measure(s)
Area Under the ROC Curve (AUC) for Malignancy Prediction — At the time of availability of pathology results, up to 6 months after index chest CT For each pure imaging AI model (MVCS, LungDoc, United Imaging model), the AUC of the receiver operating characteristic curve for predicting malignant versus benign pulmonary nodules, based on continuous malignancy probabilities or suspicion scores. AUCs will be reported with 95% confidence intervals, and pairwise comparisons will be conducted using DeLong's test.
Trial sites (5)
Facility
City
Region
Status
Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
Chongqing
Chongqing Municipality
Guangdong Provincial People's Hospital
Guangzhou
Guangdong
Zhujiang Hospital, Southern Medical University
Guangzhou
Guangdong
Affiliated Hospital of Xuzhou Medical University
Xuzhou
Jiangsu
Zhejiang University
Hangzhou
Zhejiang
More Guangdong Provincial People's Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.